Bisphosphonate treatment in the oim mouse model alters bone modeling during growth

Abstract Osteogenesis imperfecta (OI) is a heritable disease, which results from an abnormal amount or structure of Type I collagen. Bisphosphonates, a class of synthetic antiresorptive drugs, used in osteoporosis management, are also used to decrease fracture incidence and improve quality of life i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomechanics 2008-12, Vol.41 (16), p.3371-3376
Main Authors: Rao, S.H, Evans, K.D, Oberbauer, A.M, Martin, R.B
Format: Article
Language:English
Subjects:
Animals
Bisphosphonate
Bone
Bone Development - drug effects
Bone Remodeling - drug effects
Bones
Diphosphonates - administration & dosage
Disease Models, Animal
Dose-Response Relationship, Drug
Female
Femur - drug effects
Femur - physiopathology
Geometry
Male
Medical research
Mice
Oim mouse
Organ Size - drug effects
Osteogenesis imperfecta
Osteogenesis Imperfecta - drug therapy
Osteogenesis Imperfecta - physiopathology
Pamidronate
Physical Medicine and Rehabilitation
Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Osteogenesis imperfecta (OI) is a heritable disease, which results from an abnormal amount or structure of Type I collagen. Bisphosphonates, a class of synthetic antiresorptive drugs, used in osteoporosis management, are also used to decrease fracture incidence and improve quality of life in children with OI. In this study, we used the oim mouse to test the hypotheses that pamidronate treatment during active growth (1) produces larger, stronger, stiffer long bone diaphyses without altering bone material properties, and (2) negatively impacts longitudinal bone growth. Our results indicate that femoral cross-sectional moment of inertia in the distal metaphysis tended to increase with pamidronate treatment and that the treated bones are thicker and structurally stiffer, but shorter than their control-dose counterparts.
ISSN:0021-9290
1873-2380
DOI:10.1016/j.jbiomech.2008.09.028